Scientific Plenary I: Snap, Crackle, PARP

Scientific Plenary

Moderators:

  • John Chan, MD, California Pacific & Palo Alto Medical Foundation/Sutter Health Research Institute, San Francisco, CA
  • Barbara Norquist, MD, University of Washington Medical Center, Seattle, WA

Distillant:

  • Kathleen Moore, MD, University of Oklahoma, Oklahoma City, OK

Description: For those who like high impact science but have short attention spans, we present Snap, Crackle, PARP! Come and hear the latest PARP inhibitor related science, in a session designed with maximal efficiency in mind.

Location: Kamehameha 3

ABSTRACT 1
Time without symptoms or toxicity in patients with recurrent ovarian cancer receiving niraparib maintenance treatment versus placebo: A TWIST analysis of the ENGOT-OV16/NOVA trial

U.A. Matulonis1, L. Walder2, T.J. Nøttrup3, A.V. Tinker4, S. Mahner5, M. Gil-Martin6, M. Fabbro7, S. Banerjee8, R.M. Wenham9, K. Woie10, L. Gilbert11, P. Harter12, A. Casado Herráez13, P. Follana14, J.A. Ledermann15, C. Leroy16, P. Scollo17, B. Lund18, S. Malander19, M. Fisher2, H. Guy2 and M.R. Mirza20
1Dana-Farber Cancer Institute, Boston, MA, USA, 2FIECON Ltd, St Albans, United Kingdom, 3Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark, 4British Colombia Cancer Agency, Vancouver, BC, Canada, 5Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) Study Group and Department of Obstetrics and Gynecology, University Hospital, Ludwig-Maximilians, University of Munich, Munich, Germany, 6Institut Català d’Oncologia-IDIBELL, L’hospitalet-Barcelona, Barcelona, Spain, 7Groupe d’Investigateurs Nationaux pour l’Etude des Cancers Ovariens (GINECO) and Institut du Cancer de Montpellier, Montpellier, France, 8The Royal Marsden NHS Foundation Trust, London, United Kingdom, 9H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA, 10Haukeland University Hospital, Bergen, Norway, 11McGill University Health Centre, Montreal, QC, Canada, 12Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) Study Group and Department of Gynecologic Oncology, Kliniken Essen Mitte, Essen, Germany, 13Hospital Universitario San Carlos, Madrid, Spain, 14Groupe d’Investigateurs Nationaux pour l’Etude des Cancers Ovariens (GINECO) and Centre Antoine Lacassagne, Nice, France, 15University College London, London, United Kingdom, 16Centre Hospitalier Régional de la Citadelle, Liège, Belgium, 17Cannizzaro Hospital, Catania, Italy, 18The Nordic Society of Gynecological Oncology (NSGO) and Aalborg University, Aalborg, Denmark, 19The Nordic Society of Gynecological Oncology (NSGO) and Lund University Hospital, Lund, Sweden, 20The Nordic Society of Gynecological Oncology (NSGO) and Righospitalet-Copenhagen University Hospital,
Copenhagen, Denmark

ABSTRACT 2
Baseline platelet count and body weight as predictors of early dose modification in the QUADRA trial of niraparib monotherapy for the treatment of heavily pretreated (≥4th line), advanced, recurrent high-grade serous ovarian cancer

U.A. Matulonis1, B.J. Monk2, A.A. Secord3, M.A. Geller4, D.S. Miller5, N.G. Cloven6, G.F. Fleming7, A.E. Wahner Hendrickson8, M. Azodi9, P.A. DiSilvestro10, A.M. Oza11, M. Cristea12, J.S. Berek13, J.K. Chan14,15, Y. Li16, K. Luptakova16, S.J. Hazard16 and K.N. Moore17
1Harvard Medical School, Boston, MA, USA, 2University of Arizona College of Medicine, Phoenix Creighton University School of Medicine at St. Joseph’s Hospital, Phoenix, AZ, USA, 3Duke Cancer Institute, Duke University Health System, Durham, NC, USA, 4University of Minnesota Medical School, Minneapolis, MN, USA, 5The University of Texas Southwestern Medical Center, Dallas, TX, USA, 6Texas Oncology, Fort Worth, TX, USA, 7The University of Chicago Medicine, Chicago, IL, USA, 8Mayo Clinic, Rochester, MN, USA, 9Smilow Cancer Hospital at Yale and Yale University, New Haven, CT, USA, 10Women & Infants Hospital, Brown University, Providence, RI, USA, 11University Health Network and Princess Margaret Cancer Centre, Toronto, ON, Canada, 12City of Hope National Medical Center, Duarte, CA, USA, 13Stanford Cancer Institute, Stanford, CA, USA, 14California Pacific, Palo Alto, CA, USA, 15Sutter Health, San Francisco, CA, USA, 16TESARO, Inc., Waltham, MA, USA, 17Stephenson Cancer Center, The University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA

ABSTRACT 3
A prospective evaluation of tolerability of niraparib dosing based upon baseline body weight and platelet count: Blinded pooled interim safety data from the ENGOT-OV26/PRIMA study

B.J. Monk1, M.R. Mirza2, I. Vergote3, Y. Li4, I. Malinowska4, D. Gupta4, W.A. Graybill5, B. Pothuri6 and A. Gonzalez-Martin7
1Arizona Oncology (US Oncology Network), University of Arizona College of Medicine, Phoenix Creighton University School of Medicine at St. Joseph’s Hospital, Phoenix, AZ, USA, 2The Nordic Society of Gynecological Oncology (NSGO) and Righospitalet-Copenhagen University Hospital, Copenhagen, Denmark, 3Belgian Gynecologic Oncology Group (BGOG) and University of Leuven, Leuven Cancer Institute, Leuven, Belgium, 4TESARO, Inc., Waltham, MA, USA, 5Medical University of South Carolina, Charleston, SC, USA, 6NYU Langone Medical Center, New York, NY, USA, 7Grupo Español de Investigación en Cáncer de Ovario (GEICO) y Clinica Universidad de Navarra, Madrid, Spain

ABSTRACT 4
The effect of age on efficacy and safety outcomes with rucaparib: A post hoc exploratory analysis of ARIEL3, a phase III, randomized, placebo-controlled maintenance study in patients with recurrent ovarian carcinoma

J.A. Ledermann1, A.M. Oza2, D. Lorusso3, C.A. Aghajanian4, A. Oaknin5, A. Dean6, N. Colombo7, J.I. Weberpals8, A.R. Clamp9, G. Scambia10, A. Leary11, R.W. Holloway12, M. Amenedo Gancedo13, P.C.C. Fong14, J.C. Goh15,16, F.J. Backes17, S. Banerjee18, S. Goble19, T. Cameron19 and R.L. Coleman20
1UCL Cancer Institute and UCL Hospitals, London, United Kingdom, 2Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada, 3Fondazione IRCCS Istituto Nazionale dei Tumori and MITO, Milan, Italy, 4Memorial Sloan Kettering Cancer Center, New York, NY, USA, 5Vall d’Hebrón University Hospital, Vall d’Hebrón Institute of Oncology (VHIO), Barcelona, Spain, 6St John of God Subiaco Hospital, Subiaco, Australia, 7European Institute of Oncology and University of Milan-Bicocca, Milan, Italy, 8Ottawa Hospital Research Institute, Ottawa, ON, Canada, 9The Christie NHS Foundation Trust and University of Manchester, Manchester, United Kingdom, 10Policlinico Universitario A. Gemelli IRCCS Università Cattolica del Sacro Cuore Roma, Rome, Italy, 11Gustave Roussy Cancer Center, INSERM U981, and Groupe d’Investigateurs Nationaux pour l’Etude des Cancers Ovariens (GINECO), Villejuif, France, 12Florida Hospital Cancer Institute, Orlando, FL, USA, 13Oncology Center of Galicia, La Coruña, Spain, 14Auckland City Hospital, Grafton, New Zealand, 15Royal Brisbane and Women’s Hospital, Herston, QLD, Australia, 16University of Queensland, St Lucia, QLD, Australia, 17The Ohio State University, James Cancer Center, Columbus, OH, USA, 18The Royal Marsden NHS Foundation Trust, London, United Kingdom, 19Clovis Oncology Inc., Boulder, CO, USA, 20The University of Texas MD Anderson Cancer Center, Houston, TX, USA

ABSTRACT 5
Costs and benefits of tumor testing for BRCA mutations in high-grade serous ovarian cancer as a triage for confirmatory genetic testing

J.S. Kwon1, A.V. Tinker2, A. Karsan3, K.A. Schrader2 and S. Sun2
1University of British Columbia, Vancouver, BC, Canada, 2British Columbia Cancer Agency, Vancouver, BC, Canada, 3BC Cancer, Vancouver, BC, Canada

ABSTRACT 6
Simultaneous clinical testing for germline and somatic mutations in ovarian carcinoma (OC): Mutation rate and impact on therapeutic decisions

S. Jorge1, A.S. McFaddin1, K.M. Doll1, K.P. Pennington2, B.M. Norquist3, E.M. Swisher1, R.L. Bennett1 and C.C. Pritchard3
1University of Washington Medical Center, Seattle, WA, USA, 2University of Washington School of Medicine, Seattle, WA, USA, 3University of Washington, Seattle, WA, USA

ABSTRACT 7
PARPi after PARPi in epithelial ovarian cancer

K.G. Essel1, K. Behbakht2, T. Lai3, L. Hand4, E. Evans1, J.D. Dvorak1, K. Ding5, G.E. Konecny3 and K.N. Moore6
1The University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA, 2University of Colorado Denver, Aurora, CO, USA, 3University of California, Los Angeles, Los Angeles, CA, USA, 4Magee-Womens Hospital of UPMC, Pittsburgh, PA, USA, 5The University of Oklahoma, Oklahoma City, OK, USA, 6The University of Oklahoma, Stephenson Cancer Center, Oklahoma City, OK, USA

Top